Skip to main content

Table 2 Additional or combination medication and mortality

From: Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer

 

Total (n = 31)

Respiratory failure (n = 18)

No respiratory failure (n = 13)

p value

Favipiravir, n (%)

31 (100%)

18 (100%)

13 (100%)

1.000b)

Heparin, n (%)

15 (48.4%)

11 (61.1%)

4 (30.8%)

0.149b)

Steroid, n (%)

25 (80.6%)

17 (94.4%)

8 (61.5%)

0.059 b)

Number of deaths, n (%)

10 (32.2%)

10 (55.6%)

0 (0%)

0.001b)*

  1. *P < 0.05 was considered statistically significant
  2. a) Mann − Whitney U test